PharmaEssentia Corporation (LUX:261280558)

PharmaEssentia Statistics

Total Valuation

PharmaEssentia has a market cap or net worth of EUR 5.20 billion. The enterprise value is 4.65 billion.

Market Cap	5.20B
Enterprise Value	4.65B

Important Dates

The next estimated earnings date is Thursday, November 13, 2025.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	Aug 11, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.68%
Shares Change (QoQ)	+0.10%
Owned by Insiders (%)	8.83%
Owned by Institutions (%)	8.27%
Float	291.39M

Valuation Ratios

The trailing PE ratio is 44.13 and the forward PE ratio is 25.76.

PE Ratio	44.13
Forward PE	25.76
PS Ratio	14.15
PB Ratio	6.26
P/TBV Ratio	6.32
P/FCF Ratio	91.49
P/OCF Ratio	57.21
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 43.50, with an EV/FCF ratio of 81.74.

EV / Earnings	39.42
EV / Sales	13.15
EV / EBITDA	43.50
EV / EBIT	47.80
EV / FCF	81.74

Financial Position

The company has a current ratio of 7.71, with a Debt / Equity ratio of 0.03.

Current Ratio	7.71
Quick Ratio	7.24
Debt / Equity	0.03
Debt / EBITDA	0.25
Debt / FCF	0.48
Interest Coverage	138.58

Financial Efficiency

Return on equity (ROE) is 15.04% and return on invested capital (ROIC) is 7.78%.

Return on Equity (ROE)	15.04%
Return on Assets (ROA)	7.12%
Return on Invested Capital (ROIC)	7.78%
Return on Capital Employed (ROCE)	11.80%
Revenue Per Employee	2.81M
Profits Per Employee	900,430
Employee Count	131
Asset Turnover	0.41
Inventory Turnover	1.23

Taxes

Income Tax	-22.17M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.58% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-15.58%
50-Day Moving Average	16.85
200-Day Moving Average	17.81
Relative Strength Index (RSI)	39.93
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PharmaEssentia had revenue of EUR 367.88 million and earned 117.96 million in profits. Earnings per share was 0.32.

Revenue	367.88M
Gross Profit	324.32M
Operating Income	101.23M
Pretax Income	95.79M
Net Income	117.96M
EBITDA	104.66M
EBIT	101.23M
Earnings Per Share (EPS)	0.32

Balance Sheet

The company has 605.13 million in cash and 27.50 million in debt, giving a net cash position of 577.63 million.

Cash & Cash Equivalents	605.13M
Total Debt	27.50M
Net Cash	577.63M
Net Cash Per Share	n/a
Equity (Book Value)	831.16M
Book Value Per Share	2.25
Working Capital	653.07M

Cash Flow

In the last 12 months, operating cash flow was 90.97 million and capital expenditures -34.09 million, giving a free cash flow of 56.89 million.

Operating Cash Flow	90.97M
Capital Expenditures	-34.09M
Free Cash Flow	56.89M
FCF Per Share	n/a

Margins

Gross margin is 88.16%, with operating and profit margins of 27.52% and 32.06%.

Gross Margin	88.16%
Operating Margin	27.52%
Pretax Margin	26.04%
Profit Margin	32.06%
EBITDA Margin	28.45%
EBIT Margin	27.52%
FCF Margin	15.46%

Dividends & Yields

This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 0.11%.

Dividend Per Share	0.02
Dividend Yield	0.11%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.68%
Shareholder Yield	-0.56%
Earnings Yield	2.27%
FCF Yield	1.09%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PharmaEssentia has an Altman Z-Score of 30.12 and a Piotroski F-Score of 6.

Altman Z-Score	30.12
Piotroski F-Score	6